BOB Capital Markets Ltd.
Strong Q1 beat with EBITDA/PAT of Rs 2.7bn/Rs 2.1bn coming in 17%/ 39% ahead of consensus due to margin recovery
Ajanta Pharma Ltd. is trading above all available SMAs
More from Ajanta Pharma Ltd.
Recommended